Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Starpharma Holdings Limited ( (AU:SPL) ).
Starpharma Holdings Limited has entered into a collaboration and license agreement with Genentech, a Roche Group member, to develop cancer therapies using Starpharma’s DEP® technology. This partnership will see Starpharma receive an upfront payment and potential milestone payments totaling up to USD $564 million, along with royalties on global sales. The collaboration highlights Starpharma’s strategic focus on forming impactful partnerships to expand its market reach and enhance therapeutic offerings, positioning the company strongly within the oncology sector.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology, which it has been advancing for over two decades. The company focuses on developing drug delivery technologies, particularly through its proprietary DEP® platform, which enhances drug solubility, efficacy, and toxicity profiles. Starpharma’s technology is applicable across various drug classes, including small molecules, peptides, proteins, chemotherapeutics, and antibody-drug conjugates.
YTD Price Performance: 18.18%
Average Trading Volume: 318,370
Technical Sentiment Signal: Hold
Current Market Cap: A$54.37M
Find detailed analytics on SPL stock on TipRanks’ Stock Analysis page.